Fusion-Based Biomarkers
for Targeted Therapy

We have integrated DNA and RNA sequencing results
for detection of fusion genes with higher sensitivity.

DNA+RNA-based analysis
of Fusion

RNA sequencing is a supplement to fusion detection

In Chinese solid tumor cohort, 60.2% of fusion could
be identified both in DNA&RNA, 21.4% of fusion was
DNA only and 18.4% was RNA only.

Gene fusions

Overview of gene rearrangement in Chinese
cohort including kinase gene fusions and LOF
rearrangement of tumor suppressor genes.
Different driver genes and their partners were
identified in the cohort. The thickness of the line
indicated the number of cases with relative gene

NTRK family gene fusions

Among 5,388 clinical cases, 22 (0.4%) patients
were found harboring NTRK1/3 fusions by
next-generation sequencing testing, which was
further confirmed by pan-Trk IHC or PCR.
NTRK fusions were detected more in fibrosarcoma
and colorectal cancer at a ratio of 11.1% and 1.1%,

FGFR family gene fusions

From over 4,000 solid tumor patients, 6.6% had FGFR 1-4 variations. The incidences of genomic
alterations on FGFR1, 2, 3, and 4 were 2.8%, 1.6%, 1.2% and 1%, respectively. Amplification was the
most common variation type of FGFR, which accounted for 47% of all the genomic alterations, followed
by mutations (41.5%) and fusions (11.4%).

Targeted Therapy


The 5000+ Chinese solid tumor patients
included 58.3% males and 41.7% females.
Among patients with BRCA1/2 mutations,74.7%
patients harbored somatic mutations. 24.3%
patients harbored germline mutations and 1.0%
patients harbored both somatic and germline


Distriution and frequency of ERBB2 variants in
5000+ Chinese solid tumor patients.


We have leveraged multiple techniques (DNA, RNA, IHC, etc.) to help identify
immunotherapy-related biomarkers for our patients.


The landscape of tumor mutational burden(TMB)
in 10,000+ Chinese solid tumor patients.


The landscape of PD-L1 expression on varoius
types of tumor cells in 3,000+Chinese solid
tumor patients.